Cerecor to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
August 22 2016 - 9:10AM
Business Wire
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical
company developing treatments to make a difference in the lives of
patients with neurological and psychiatric disorders, today
announced it will be featured as a presenting company at the 18th
Annual Rodman & Renshaw Global Investment Conference, sponsored
by H.C. Wainwright & Co., LLC. The conference is being
held on September 11-13, 2016, at Lotte New York Palace Hotel
in New York City.
Dr. Uli Hacksell, President and Chief Executive Officer of
Cerecor, will provide an overview of the Company's business during
the live presentation and will be available to participate in
one-on-one meetings with investors who are registered to attend the
conference.
If you are an institutional investor, and would like to attend
the Company’s presentation, please click on the following link
(www.rodmanevents.com) to register for the Rodman & Renshaw
conference. Once your registration is confirmed, you will be
prompted to log into the conference website to request a one-on-one
meeting with the Company.
Presentation Date:
September 12, 2016 Time: 2:35 pm (Eastern Time) Location: Adam’s
Room; Lotte New York Palace Hotel in New York City
The presentation will be webcast live. To access the webcast,
please visit http://wsw.com/webcast/rrshq26/cerc. The webcast
replay will remain available for 90 days following the live
presentation.
About Cerecor
Cerecor is a biopharmaceutical company with the goal of becoming
a leader in the development of innovative drugs that make a
difference in the lives of patients with neurological and
psychiatric disorders. We are committed to the development of drugs
that improve lives by applying our extensive knowledge and
experience in central nervous system
disorders. Cerecor is currently pursuing the development
of two clinical Phase 2-stage product candidates: CERC-301 and
CERC-501.
CERC-301 is currently in Phase 2 development as an oral,
rapidly acting adjunctive treatment of patients with severe major
depressive disorder, or MDD, who are failing to achieve an adequate
response to their current antidepressant treatment with a rapid
onset of effect. Cerecor received fast track designation by the
United States Food and Drug Administration in November 2013 for
CERC-301 for the treatment of MDD. CERC-301 belongs to a class of
compounds known as antagonists, or inhibitors, of the
N-methyl-D-aspartate, or NMDA, receptor, a receptor subtype of the
glutamate neurotransmitter system that is responsible for
controlling neurological adaptation. We believe CERC-301 will be a
first-in-class medication that will cause a significant reduction
in depressive symptoms in a matter of days, as compared to weeks or
months with conventional therapies, because it specifically blocks
the NMDA receptor subunit 2B, which we believe provides rapid and
significant antidepressant activity without the adverse side effect
profile of non-selective NMDA receptor antagonists.
CERC-501 is currently in Phase 2 development for smoking
cessation. CERC-501 is a potent and selective kappa opioid
receptor, or KOR, antagonist. KORs are believed to play key roles
in modulating stress, mood and addictive behaviors. Ultimately,
Cerecor intends to pursue development of CERC-501 for the treatment
of substance use disorders more broadly (e.g., nicotine,
alcohol, and/or cocaine) and as an adjunctive treatment of MDD. In
addition to Cerecor’s Phase 2 trial, two externally-funded clinical
trials are being conducted to evaluate the use of CERC-501 in
treating cocaine addiction and mood disorders. One study is being
conducted under the auspices of the National Institute of Mental
Health and the second study is being funded by a private
foundation.
In addition to our two clinical Phase 2-stage product
candidates, Cerecor has one preclinical stage asset,
CERC-406, a brain penetrant catechol-O-methyltransferase, or COMT,
inhibitor with potential procognitive activity.
For more information about the Company and its products, please
visit www.cerecor.com or contact Mariam E. Morris,
Chief Financial Officer, at (443) 304-8002.
Forward-Looking Statements
This press release may include forward-looking statements made
pursuant to the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are statements that are not historical
facts. Such forward-looking statements are subject to significant
risks and uncertainties that are subject to change based on various
factors (many of which are beyond Cerecor’s control), which could
cause actual results to differ from the forward-looking statements.
Such statements may include, without limitation, statements with
respect to Cerecor’s plans, objectives, projections, expectations
and intentions and other statements identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “continue,”
“seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,”
“estimates,” “intends,” “plans,” “potential” or similar expressions
(including their use in the negative), or by discussions of future
matters such as the development of product candidates or products,
technology enhancements, possible changes in legislation, and other
statements that are not historical. These statements are based upon
the current beliefs and expectations of Cerecor’s management but
are subject to significant risks and uncertainties, including those
detailed in Cerecor’s filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the
forward-looking statements. Except as required by applicable
law, Cerecor expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Cerecor’s expectations with respect thereto or any change in
events, conditions or circumstances on which any statement is
based.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160822005114/en/
MacDougall Biomedical CommunicationsDoug MacDougall or Joe
Rayne, 781-235-3060ir@cerecor.com
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From Jul 2023 to Jul 2024